Business Context and Reporting Period
Propanc Biopharma, Inc., a Delaware corporation, filed this Form 8-K on October 2, 2019, to report the entry into a Material Definitive Agreement. The company is headquartered in Camberwell, Australia.
Key Financial Metrics
This filing reports a specific financing transaction rather than periodic financial performance metrics such as revenue, profit, or operating cash flow. The filing text does not provide a clear value for these standard financial indicators.
- Capital Raised: $125,000 (Purchase Price).
- Debt Instrument: Convertible Redeemable Promissory Note with a principal amount of $131,000.
- Interest Rate: 8% per annum.
- Maturity Date: October 1, 2020.
Material Changes and Transaction Terms
The company entered into a Securities Purchase Agreement with a single accredited investor. The transaction involves the issuance of a Convertible Redeemable Promissory Note with the following material terms:
- Conversion Rights: The Note may be converted into common stock at a 40% discount to the lowest closing bid price of the Common Stock over the ten trading days immediately prior to the conversion notice.
- Ownership Cap: Conversion is limited to prevent the investor and affiliates from beneficially owning more than 4.99% of the company, though this may be increased to 9.99% with 60 days' prior written notice.
- Redemption Provisions: The Company may redeem the Note prior to April 2, 2020, subject to escalating penalties based on timing:
- Within 60 days: 115% of face amount plus accrued interest.
- Days 61-120: 125% of face amount plus accrued interest.
- Days 121-180: 135% of face amount plus accrued interest.
- Default: The Note becomes immediately due and payable upon default without demand or notice.
Guidance, Risks, and Unusual Items
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard terms of the debt instrument. The issuance of the securities was made in reliance on the exemption provided by Section 4(a)(2) of the Securities Act for private transactions not involving a public offering.
Investor Verification Checklist
- Verify the current cash position of Propanc Biopharma to assess the ability to service the $131,000 principal plus 8% interest by the October 1, 2020 maturity date.
- Review the company's current share count to calculate the potential dilution impact if the Note is converted at the 40% discount.
- Confirm the identity of the "accredited investor" and any potential conflicts of interest.
- Examine the full text of the Securities Purchase Agreement (Exhibit 10.1) and the Note (Exhibit 4.1) for additional covenants or restrictions not summarized in this 8-K.